Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2023

Magro CM, Kalomeris TA, Mo JH, Rice M, Nuovo G. Lichen sclerosus: A C5B-9 mediated chronic microvascular injury syndrome potentially reflective of common adult comorbidities. Ann Diagn Pathol. 2023;63:152098.

Bakht MK, Yamada Y, Ku S-, Venkadakrishnan VB, Korsen JA, Kalidindi TM, et al. Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer. Nat Cancer. 2023;4(5):699-715.

Hissong E, Zhao L, Shi J. Clinicopathologic and Molecular Features of Pancreatic Ductal Adenocarcinomas Harboring Alterations in COMPASS-like Complex Genes. Arch Pathol Lab Med. 2023;147(9):1050-1059.

Vidotto T, Imada EL, Faisal F, Murali S, Mendes AA, Kaur H, et al. Association of self-identified race and genetic ancestry with the immunogenomic landscape of primary prostate cancer. JCI Insight. 2023;8(3).

Karaaslan S, Dilcher TL, Abdelsayed M, Goyal A. Significant outcomes associated with high-risk human papillomavirus negative Papanicolaou tests. J Am Soc Cytopathol. 2023;12(3):189-196.

Brown-Burke F, Hwang I, Sloan S, Hinterschied C, Helmig-Mason JB, Long M, et al. PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma. Blood Adv. 2023;7(20):6211-6224.

Thomas N, Dreval K, Gerhard DS, Hilton LK, Abramson JS, Ambinder RF, et al. Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma. Blood. 2023;141(8):904-916.

Pakula H, Omar M, Carelli R, Pederzoli F, Fanelli GN, Pannellini T, et al. Distinct mesenchymal cell states mediate prostate cancer progression. bioRxiv. 2023.

Boyraz B, Post MD, Hasserjian RP, Oliva E. Follicular Dendritic Cell Sarcoma of Uterine Corpus: Report of 2 Cases. Int J Gynecol Pathol. 2023;42(4):390-397.

Quintanilha JC, Graf RP, Fisher VA, Oxnard GR, Ellis H, Panarelli N, et al. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden. JAMA Netw Open. 2023;6(1):e2252244.